Gaucher Disease and Cancer: Concept and Controversy. (7th June 2011)

• Record Type: Journal Article
• Authors: Choy, Francis Y. M.; Campbell, Tessa N.
• Other Names: Jetten Anton M. Academic Editor.
• Is Part Of: International journal of cell biology. Volume 2011(2011)
• Publication Date: 2011-06-07
• Subjects: Cytology -- Periodicals; Cell Biology; Cytology; Periodicals; Electronic journals -- Sciences; Electronic journals -- Biology; Periodicals; 571.6
• DOI: 10.1155/2011/150450
• Languages: English
• ISSNs: 1687-8876

Abstract

Abstract : Gaucher disease is an inherited disorder caused by a deficiency in the lysosomal hydrolase glucocerebrosidase. There is a wide spectrum of clinical presentations, with the most common features being hepatosplenomegaly, skeletal disease, and cytopenia. Gaucher disease has been classified into three broad phenotypes based upon the presence or absence of neurological involvement: Type 1 (nonneuronopathic), Type 2 (acute neuronopathic), and Type 3 (subacute neuronopathic). The two main treatment options include enzyme replacement therapy and substrate reduction therapy. Recently, discussion has escalated around the association of Gaucher disease and cancer, with conflicting reports as to whether Gaucher patients have an increased risk of malignancy. In this review, we present both the concept and controversy surrounding the association of Gaucher disease with cancer.